Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history   INDIANAPOLIS , Feb.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3K α inhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's

<p>Evidence of harmful knockoff tirzepatide escalates &nbsp; INDIANAPOLIS, December 23, 2024 – In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit import of knock-off tirzepatide products.&nbsp; The</p>

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity&nbsp; INDIANAPOLIS , Dec. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County,

INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024 . In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a

<p>Today, Lilly sued HRSA over its purported rejection of Lilly’s plan to change the way it offers reduced prices on its medicines in the 340B program, through its technology partner Kalderos. The 340B program currently uses a slow, indirect “product replenishment” model that was created by for-profit</p>

<p>INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective Oct. 21, 2024. In this role, Fuchs will provide vision, strategic direction and overall leadership of AI initiatives across Lilly,</p>

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more

Company ups manufacturing investment in Limerick by $1 billion ; unveils new $800 million&nbsp;Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) today

INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:&nbsp;LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.